Lineage Cell Therapeutics Inc (LCTX) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Industry, else..
 
Lineage Cell Therapeutics Inc   (NYSE: LCTX)
 

Lineage Cell Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LCTX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) -61.34 % 5.15 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) -38.03 % -11.92 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 19.87 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) -11.48 % 1.16 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 51.46 % 8.2 % 8.65 % 10.59 %


LCTX's Growth Comparisons in II. Quarter 2026




As Lineage Cell Therapeutics Inc 's sales faded by -61.34% year on year in the second quarter 2026, the Biotechnology & Pharmaceuticals industry grew by 5.15%, Lineage Cell Therapeutics Inc 's second quarter 2026 performance was trailing the Biotechnology & Pharmaceuticals industry in the second quarter 2026, and underperformed the 8.91% Revenue growth in the Healthcare sector. Weak second quarter sales, in Biotechnology & Pharmaceuticals industry and within the Healthcare sector, were reflected in Lineage Cell Therapeutics Inc results which underperformed overall market.

Top-line fell by -38.03% from the first quarter results. Comparing the annual growth, sales of 51.46% on average in last five years, to the S & P 500's, including only Businesses with the second quarter 2026 financial results, average yearly sales growth is 10.59%. Lineage Cell Therapeutics Inc grew faster than the market.

LCTX Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Collaboration Revenues
-
-
Royalties license and other revenues
-
-
Upfront License Fees
-58.21 %
23.02 %
Total
-61.34 %
-38.03 %


Growth Rates of LCTX's Income in the second quarter 2026


LCTX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - 434.95 % 4.62 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) - -48.89 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) - 954.66 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) - 230.06 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - -18.41 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -78.96 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) - - -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - -86.66 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - -59.21 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -11.5 % 0.17 % -28.52 %

LCTX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -78.9 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) - -86.69 % -0.77 % 27.07 %
Y / Y Net Income Change (Q2 TTM) - 103.06 % 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) - -7.95 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth - -8.55 % 9.21 % 22.96 %

LCTX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -82.2 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - - -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - 49.32 % 0.17 % -28.52 %



LCTX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -82.15 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) - -88.25 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - - 4.93 %
EPS Net 5 Year Avg. Change - -8.55 % 9.21 % 22.96 %



Lineage Cell Therapeutics Inc reported bottom-line of $ -0.03 in the second quarter, compare to $ -0.13 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry fell by -82.15%, while Healthcare sector decreased by -26.26%, and overall market improved by 90.69%.

Bottom-line fell by -38.03% from the first quarter results. Comparing the annual growth, income per share of 51.46% on average in last five years, to the S & P 500's, including only Businesses with the second quarter 2026 earnings, average yearly income per share growth is 22.96%. Lineage Cell Therapeutics Inc grew faster than the market.

LCTX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) - 6160.46 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) - -53.57 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) - 14 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) - 16.85 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - -14.51 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - 36.63 % - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) - 784.84 % - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 23.25 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) 671.43 % 32.26 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) 96.36 % -1.95 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) -2.38 % -4.97 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) 19.58 % 8.05 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change 52.16 % 9.64 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.